Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes
โ Scribed by Emmenegger, U.; Zehnder, R.; Frey, U.; Reimers, A.; Spaeth, P.J.; Neftel, K.A.
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 38 KB
- Volume
- 64
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
โฆ Synopsis
Derailed T-cell activation can give rise to life-threatening macrophage activation, the final common pathway of the different forms of reactive macrophage activation syndromes (rMAS). Besides inappropriate activation of the immune system, impaired termination of immune responses might be another mechanism leading to rMAS. The Fas (CD95)/Fas ligand (CD95 ligand) system functions in turning off immune responses by executing activation-induced cell death (AICD). Soluble Fas (sFas) and Fas ligand (sFasL) can interfere with their corresponding membrane-bound counterparts, qualifying them as potential parameters of impaired immune termination. Hence, sFas and sFasL were analyzed in sera of rMAS patients. We show that soluble Fas/CD95 (sFas) is elevated >2 SD over the mean of controls in all 8 rMAS episodes studied (mean 12.08 ยฑ 6.12 ng/mL, range 3.7-20.2; controls 2.46 ยฑ 0.49, range 1.5-2.9). sFasL was detected during five rMAS episodes (0.70 ยฑ 0.49 ng/mL, range 0.16-1.28; controls all below the limit of detection of 0.1). In addition, both parameters decrease during convalescence, reflecting clinical evolution. In conclusion, sFas seems to be consistently elevated during acute rMAS. sFasL is detected only in a subgroup of our adult rMAS patients extending the recent finding of sFasL elevation in a majority of children with macrophage activation syndromes (Hasegawa et al.
๐ SIMILAR VOLUMES
We measured serum soluble Fas ligand (sFasL) in a patient with natural killer cell lymphoma, and investigated relationship between sFasL and liver dysfunction. An elevated level of sFasL was decreased after local radiation therapy, and liver function improved. When lymphoma relapsed, liver dysfuncti
Many tumour cells express both Fas and its ligand (FasL) on their surface and it has remained a mystery why such cells do not simply kill themselves. It remains to be determined whether Fas and FasL are expressed in human hepatoblastomas and if so, what is responsible for the possible Fas resistance